The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Thyme Care closes $95M Series C to advance optimization of care, navigation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Thyme Care announced the close of a $95 million capital raise. With $55 million in equity funding, Thyme Care welcomes new investor Concord Health Partners with participation from all existing investors, including CVS Health Ventures, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Frist Cressey Ventures, and Foresite Capital. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Thyme Care raises $97M in Series D investment

Thyme Care has announced a $97M Series D fundraise from current investors CVS Health Ventures, Foresite Capital, a16z Bio + Health, Concord Health Partners, Town Hall Ventures, AlleyCorp, and Frist Cressey Ventures. New strategic investors include Morgan Health, a division of JPMorganChase focused on employer-sponsored healthcare, as well as Humana, Texas Oncology, and Memorial Hermann Health System, bringing Thyme Care’s total capital raised to $275M.
In Brief

People across Croatia gain access to advanced radiosurgery close to home at UPMC Hillman Cancer Center in Zabok

UPMC Hillman Cancer Center at Zabok General Hospital in Croatia is expanding access to the most advanced radiosurgery services for people across the country with the introduction of the Varian TrueBeam stereotactic body radiation therapy and stereotactic radiosurgery system. The new system delivers radiosurgery treatment with pinpoint accuracy and image-guided precision in a shorter amount of time than current conventional treatments.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account